Form 4: Werewolf Therapeutics Director Sells Over 111K Shares

Werewolf Therapeutics Director Luke Evnin reported the sale of over 111,000 common shares through pre-arranged 10b5-1 plans.

Summary

• Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), reported sales of common stock.
• On January 13, 2026, 43,198 shares were sold at a weighted average price of $0.55 per share, with prices ranging from $0.53675 to $0.5697.
• On January 14, 2026, 30,616 shares were sold at a weighted average price of $0.57 per share, with prices ranging from $0.5524 to $0.5857.
• On January 15, 2026, 37,413 shares were sold at a weighted average price of $0.55 per share, with prices ranging from $0.5305 to $0.59.
• These transactions were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• Following these transactions, the indirect beneficial ownership of common stock stands at 2,198,642 shares.
• The shares are held indirectly through various MPM entities, and Luke Evnin disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of shares by a director and 10% owner, even under a pre-arranged 10b5-1 plan, can be interpreted as a slightly negative signal regarding the insider's view on the company's valuation or future prospects. However, the pre-planned nature reduces the immediate negative impact compared to unplanned sales.

Positives

• Transactions were conducted under a pre-established Rule 10b5-1 plan, indicating planned sales rather than a reaction to new, negative information.

Negatives

• A director and 10% owner sold a significant number of shares, totaling 111,227 shares.
• The sales occurred at relatively low prices, ranging from $0.5305 to $0.59 per share.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects or that the insider believes the stock is fully valued or overvalued.

Related Party Transactions

• Luke Evnin, a Director and 10% owner, sold shares of the company's common stock.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a negative signal, potentially impacting investor confidence and stock price.

Key Dates

Recommendation

While insider selling by a director and 10% owner can be a negative signal, the transactions were executed under a pre-established Rule 10b5-1 plan, which suggests the sales were not based on new, adverse material non-public information. This mitigates some of the negative implications. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is prudent, advising investors to monitor future developments and the company's performance.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, SEC Filing, Director, 10b5-1 Plan, Biotechnology, Stock Sale